Safety and efficacy of fedratinib, a selective oral inhibitor of Janus kinase‐2 (JAK2), in patients with myelofibrosis and low pretreatment platelet counts

Fedratinib, an oral Janus kinase‐2 (JAK2) inhibitor, is approved for patients with myelofibrosis (MF) and platelet counts ≥50 × 10(9)/l, based on outcomes from the phase 3, placebo‐controlled JAKARTA trial in JAK‐inhibitor‐naïve MF, and the phase 2, single‐arm JAKARTA2 trial in patients previously t...

Descripción completa

Detalles Bibliográficos
Autores principales: Harrison, Claire N., Schaap, Nicolaas, Vannucchi, Alessandro M., Kiladjian, Jean‐Jacques, Passamonti, Francesco, Zweegman, Sonja, Talpaz, Moshe, Verstovsek, Srdan, Rose, Shelonitda, Zhang, Jun, Sy, Oumar, Mesa, Ruben A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Haematological Malignancy‐clinical
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541243/
https://www.ncbi.nlm.nih.gov/pubmed/35476316
http://dx.doi.org/10.1111/bjh.18207

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9541243/
https://www.ncbi.nlm.nih.gov/pubmed/35476316
http://dx.doi.org/10.1111/bjh.18207

Ejemplares similares